Prediction of Chemistry of Cocrystallization and its Realistic Impact on the Enhancement of Solubility and Dissolution of Telmisartan: Molecular mechanics, ab initio and Descriptor Analysis

References

1. DesirajuG.R. Crystal engineering: A brief overview.J. Chem. Sci.2010122566767510.1007/s12039‑010‑0055‑2
   [Google Scholar]
2. PatelJ.R. CarltonR.A. NeedhamT.E. ChichesterC.O. VogtF.G. Preparation, structural analysis, and properties of tenoxicam cocrystals.Int. J. Pharm.20124361-268570610.1016/j.ijpharm.2012.07.034 22841852
   [Google Scholar]
3. ShanN. ZaworotkoM.J. The role of cocrystals in pharmaceutical science.Drug Discov. Today2008139-1044044610.1016/j.drudis.2008.03.004 18468562
   [Google Scholar]
4. BollaG. NangiaA. Pharmaceutical cocrystals: Walking the talk.Chem. Commun. (Camb.)201652548342836010.1039/C6CC02943D 27278109
   [Google Scholar]
5. ChadhaR. BhandariS. HaneefJ. KhullarS. MandalS. Cocrystals of telmisartan: Characterization, structure elucidation, Iin vivo and toxicity studies.CrystEngComm201416368375838910.1039/C4CE00797B
   [Google Scholar]
6. KuM.S. DulinW. A biopharmaceutical classification-based Right-First-Time formulation approach to reduce human pharmacokinetic variability and project cycle time from First-In-Human to clinical Proof-Of-Concept.Pharm. Dev. Technol.201217328530210.3109/10837450.2010.535826 21121705
   [Google Scholar]
7. BlagdenN. de MatasM. GavanP.T. YorkP. Crystal engineering of active pharmaceutical ingredients to improve solubility and dissolution rates.Adv. Drug Deliv. Rev.200759761763010.1016/j.addr.2007.05.011 17597252
   [Google Scholar]
8. MiroshnykI. MirzaS. SandlerN. Pharmaceutical co-crystals–an opportunity for drug product enhancement.Expert Opin. Drug Deliv.20096433334110.1517/17425240902828304 19348603
   [Google Scholar]
9. BoetkerJ. RaijadaD. AhoJ. KhorasaniM. SøgaardS.V. ArnfastL. BohrA. EdingerM. WaterJ.J. RantanenJ. In silico product design of pharmaceuticals.Asian J. Pharm. Sci.201611449249910.1016/j.ajps.2016.02.010
   [Google Scholar]
10. SharpeM. JarvisB. GoaK.L. Telmisartan.Drugs200161101501152910.2165/00003495‑200161100‑00009 11558835
    [Google Scholar]
11. TranP.H.L. TranH.T.T. LeeB.J. Modulation of microenvironmental pH and crystallinity of ionizable telmisartan using alkalizers in solid dispersions for controlled release.J. Control. Release20081291596510.1016/j.jconrel.2008.04.001 18501462
    [Google Scholar]
12. StangierJ. SuC.A.P.F. RothW. Pharmacokinetics of orally and intravenously administered telmisartan in healthy young and elderly volunteers and in hypertensive patients.J. Int. Med. Res.200028414916710.1177/147323000002800401 11014323
    [Google Scholar]
13. AkramM.A. NazirT. TahaN. AdilA. SarfrazM. NazirS.R. Designing, development and formulation of mouth disintegrating telmisartan tablet with extended release profile using response surface methodology.J. Bioequivalence Bioavailab.20157262266
    [Google Scholar]
14. ZhangY. JiangT. ZhangQ. WangS. Inclusion of telmisartan in mesocellular foam nanoparticles: Drug loading and release property.Eur. J. Pharm. Biopharm.2010761172310.1016/j.ejpb.2010.05.010 20685333
    [Google Scholar]
15. ZhongL. ZhuX. LuoX. SuW. Dissolution properties and physical characterization of telmisartan-chitosan solid dispersions prepared by mechanochemical activation.AAPS PharmSciTech201314254155010.1208/s12249‑013‑9937‑1 23430728
    [Google Scholar]
16. ZhangY. ZhiZ. JiangT. ZhangJ. WangZ. WangS. Spherical mesoporous silica nanoparticles for loading and release of the poorly water-soluble drug telmisartan.J. Control. Release2010145325726310.1016/j.jconrel.2010.04.029 20450945
    [Google Scholar]
17. BhogalaB.R. BasavojuS. NangiaA. Tape and layer structures in cocrystals of some di- and tricarboxylic acids with 4,4′-bipyridines and isonicotinamide. From binary to ternary cocrystals.CrystEngComm200579055156210.1039/b509162d
    [Google Scholar]
18. BisJ.A. ZaworotkoM.J. The 2-Aminopyridinium-carboxylate Supramolecular heterosynthon: A robust motif for generation of multiple-component crystals.Cryst. Growth Des.2005531169117910.1021/cg049622c
    [Google Scholar]
19. NeeseF. The ORCA program system.Wiley Interdiscip. Rev. Comput. Mol. Sci.201221737810.1002/wcms.81
    [Google Scholar]
20. NeeseF. Software update: The ORCA program system, version 4.0.Wiley Interdiscip. Rev. Comput. Mol. Sci.201881e132710.1002/wcms.1327
    [Google Scholar]
21. ThompsonM.A. Molecular Docking Using ArgusLab, an Efficient Shape-Based Search Algorithm and the a Score Scoring Function.Scientific Res.200420041994078
    [Google Scholar]
22. DhibarM. ChakrabortyS. BasakS. PattanayakP. ChatterjeeT. GhoshB. RaafatM. AbourehabM.A.S. Critical analysis and optimization of stoichiometric ratio of drug-coformer on cocrystal design: Molecular docking, in vitro and in vivo assessment.Pharmaceuticals (Basel)202316228410.3390/ph16020284 37259428
    [Google Scholar]
23. DhibarM. ChakrabortyS. BasakS. Assessment of effects of solvents on cocrystallization by computational simulation approach.Curr. Drug Deliv.2021181445310.2174/1567201817666200804110837 32753012
    [Google Scholar]
24. DhibarM. ChakrabortyS. KhandaiM. Solid state manipulation of telmisartan via mechanochemical activation with kaolin: An assessment of biopharmaceutical properties of amorphous phase and its physical stability.Int. J. Pharm. Sci. Res.20211250305039
    [Google Scholar]
25. HanY. PanN. LiD. LiuS. SunB. ChaiJ. LiD. Formation mechanism of surfactant-free microemulsion and a judgment on whether it can be formed in one ternary system.Chem. Eng. J.202243713538510.1016/j.cej.2022.135385
    [Google Scholar]
26. HaneefJ. AroraP. ChadhaR. Implication of coformer structural diversity on cocrystallization outcomes of telmisartan with improved biopharmaceutical performance.AAPS PharmSciTech20202111010.1208/s12249‑019‑1559‑9 31802267
    [Google Scholar]
27. CorriganO.I. StanleyC.T. Mechanism of drug dissolution rate enhancement from β-cyclodextrin-drug systems.J. Pharm. Pharmacol.2011341062162610.1111/j.2042‑7158.1982.tb04689.x 6128383
    [Google Scholar]
28. KulkarniA. SheteS. HolV. BachhavR. Novel pharmaceutical cocrystal of telmisartan and hydrochlorothiazide.Asian J. Pharm. Clin. Res.20201310411210.22159/ajpcr.2020.v13i3.36541
    [Google Scholar]
29. KunduS. KumariN. SoniS.R. RanjanS. KumarR. SharonA. GhoshA. Enhanced solubility of telmisartan phthalic acid cocrystals withinthe pH range of a systemic absorption site.ACS Omega2018311153801538810.1021/acsomega.8b02144 31458196
    [Google Scholar]
30. AlatasF. RatihH. SoewandhiS.N. Enhancement of solubility and dissolution rate of telmisartan by telmisartan-oxalic acid cocrystal formation.Int. J. Pharm. Pharm. Sci.20157423426
    [Google Scholar]
31. AroraP. KaurA. HaneefJ. ChadhaR. Solubility improvement of telmisartan by cocrystallization with citric acid.Int. J. Pharm. Sci. Res.2017837683775
    [Google Scholar]
32. MasodkarS.R. PandeS.D. AtramS.C. Development and characterization of telmisartan tablet by the use of cocrystallization technique.World J. Pharm. Pharm. Sci.20187651669
    [Google Scholar]